Physician

Robert J Behrens, MD

According to 2025 Medicare claims, Robert Behrens, MD (NPI: 1215999800) practices medical oncology in the Des Moines-West Des Moines, IA market, with the plurality of this provider's patient population coming from Polk, IA. This provider's primary affiliated billing organization is STATE UNIVERSITY OF IOWA (NPI: 1477554814; TIN: 426004813) and primary practice location at 50309-1424. Behrens is affiliated with the Caravan Health ACO 50 LLC (ACO ID: A5160), Aledade 155 National MSSP (ACO ID: A5358), Main Street Rural Health Hawthorn ACO LLC (ACO ID: A5438), and CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Behrens' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 908 traditional Medicare patients, billed 526,002 HCPCS/CPT codes, and received $10,498,956 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 1,740 prescription claims across 276 beneficiaries totaling $4,719,372 in drug costs, led by Lenalidomide (Lenalidomide). DME data shows 30 claims. No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $831,677 to $10,498,956. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $945,320 to $4,719,372. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $14,133 to $1,457.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	744	55,905	$831,677
2016	695	120,390	$1,274,868
2017	767	156,423	$1,680,754
2018	679	196,183	$1,856,142
2019	1,125	542,994	$7,574,800
2020	1,126	484,206	$8,233,306
2021	1,182	567,546	$10,129,391
2022	1,098	418,041	$8,504,212
2023	1,030	471,806	$8,713,253
2024	908	526,002	$10,498,956

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	240	1,147	$945,320
2016	222	1,149	$1,261,353
2017	221	1,076	$1,083,426
2018	209	1,139	$729,811
2019	232	1,142	$1,346,911
2020	228	1,199	$1,572,644
2021	250	1,348	$2,193,331
2022	251	1,465	$2,619,985
2023	262	1,611	$3,564,720
2024	276	1,740	$4,719,372

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	34	173	$48,546
2016	N/R	96	$7,434
2017	N/R	44	$1,747
2018	N/R	12	$234
2019	N/R	38	$4,772
2020	N/R	51	$3,048
2021	N/R	31	$2,118
2022	N/R	36	$882
2023	N/R	12	$206
2024	N/R	30	$1,028

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	256	1,317	$91
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	313	624	$80
96367	Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less	260	1,607	$20
80053	Blood test, comprehensive group of blood chemicals	254	700	$10
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	259	778	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenalidomide	Lenalidomide	81	2,219	$1,055,419
Imbruvica	Ibrutinib	43	1,222	$642,618
Tagrisso	Osimertinib Mesylate	30	900	$486,897
Calquence	Acalabrutinib Maleate	27	803	$387,406
Xtandi	Enzalutamide	26	780	$374,544

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	14	$727
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	16	$301

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

Explore More Providers

FAQ

What Medicare data is available for Robert J. Behrens, MD?

Tedicare shows public-source Medicare data for Robert J. Behrens, MD (NPI 1215999800), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Robert J. Behrens, MD have ACO affiliation data?

Robert J. Behrens, MD is shown with ACO affiliation data for Caravan Health ACO 50 LLC (MSSP, ACO ID A5160), Aledade 155 National MSSP (MSSP, ACO ID A5358), Main Street Rural Health Hawthorn ACO LLC (MSSP, ACO ID A5438), and CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Robert J. Behrens, MD?

Robert J. Behrens, MD is linked to STATE UNIVERSITY OF IOWA (billing NPI 1477554814) in the available physician profile data.

Does Robert J. Behrens, MD have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.